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Abstract
Background: Deoxycorticosterone (DOC) is an endogenous neurosteroid found in brain and serum, precursor of the
GABAergic neuroactive steroid (3a,5a)-3,21-dihydroxypregnan-20-one (tetrahydrodeoxycorticosterone, THDOC) and the
glucocorticoid corticosterone. These steroids are elevated following stress or ethanol administration, contribute to ethanol
sensitivity, and their elevation is blunted in ethanol dependence.
Methodology/Principal Findings: To systematically define the genetic basis, regulation, and behavioral significance of DOC
levels in plasma and cerebral cortex we examined such levels across 47 young adult males from C57BL/6J (B6)6DBA/2J (D2)
(BXD) mouse strains for quantitative trait loci (QTL) and bioinformatics analyses of behavior and gene regulation. Mice were
injected with saline or 0.075 mg/kg dexamethasone sodium salt at 8:00 am and were sacrificed 6 hours later. DOC levels
were measured by radioimmunoassay. Basal cerebral cortical DOC levels ranged between 1.4 and 12.2 ng/g (8.7-fold
variation, p,0.0001) with a heritability of ,0.37. Basal plasma DOC levels ranged between 2.8 and 12.1 ng/ml (4.3-fold
variation, p,0.0001) with heritability of ,0.32. QTLs for basal DOC levels were identified on chromosomes 4 (cerebral
cortex) and 14 (plasma). Dexamethasone-induced changes in DOC levels showed a 4.4-fold variation in cerebral cortex and a
4.1-fold variation in plasma, but no QTLs were identified. DOC levels across BXD strains were further shown to be co-
regulated with networks of genes linked to neuronal, immune, and endocrine function. DOC levels and its responses to
dexamethasone were associated with several behavioral measures of ethanol sensitivity previously determined across the
BXD strains by multiple laboratories.
Conclusions/Significance: Both basal and dexamethasone-suppressed DOC levels are positively correlated with ethanol
sensitivity suggesting that the neurosteroid DOC may be a putative biomarker of alcohol phenotypes. DOC levels were also
strongly correlated with networks of genes associated with neuronal function, innate immune pathways, and steroid
metabolism, likely linked to behavioral phenotypes.
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Introduction
Deoxycorticosterone (DOC) is an endogenous neurosteroid
present in the brain as well as in the peripheral circulation. It is
synthesized from progesterone, mainly in the adrenal zona
fasciculata and it is precursor of both the glucocorticoid
corticosterone and the GABAergic neuroactive steroid (3a,5a)-
3,21-dihydroxypregnan-20-one (tetrahydrodeoxycorticosterone,
THDOC). These steroids are all elevated following acute stress
[1] or ethanol administration in rats, and their elevation is blunted
in ethanol dependence [2,3,4]. The ethanol-induced increases in
neurosteroid levels are mediated by the hypothalamic-pituitary-
adrenal (HPA) axis, since they are no longer observed following
adrenalectomy/gonadectomy [5,6,7] or hypophysectomy [8].
Indeed, HPA axis regulation of neurosteroids appears to be
critical in several neuropsychiatric disorders including alcoholism.
DOC levels are regulated by hypothalamic and pituitary
activation of the HPA axis in both cynomolgus monkeys and
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18405humans, and this regulation is altered following ethanol depen-
dence [9,10]. Furthermore, we have found that dexamethasone
suppression of plasma DOC levels predicted subsequent voluntary
alcohol consumption in ethanol-naı ¨ve cynomolgus monkeys [9].
That is, ethanol-naı ¨ve monkeys that are insensitive to dexameth-
asone drink the most alcohol in a two-bottle self-administration
paradigm, suggesting that DOC responses may be putative
biomarkers of excessive drinking phenotypes.
Individual differences in vulnerability to alcoholism have a
genetic component [11,12,13,14]. Furthermore, studies in rodents
indicate a shared genetic sensitivity to ethanol, anxiety, and stress/
HPA axis response [15,16,17]. Inbred mice are an excellent
population model to study genetic and phenotypic variability. In
particular, the C57BL/6J (B6)6DBA/2J (D2) (BXD) recombinant
inbred strains have proved to be an extremely valuable reference
population to study networks of phenotypes and their modulation
by gene variants [18,19,20,21]. The parental strains, B6 and D2,
have been sequenced, and approximately five million single
nucleotide polymorphisms (SNPs) between them have been
identified. Several behavioral phenotypes for ethanol and stress/
anxiety have already been characterized across the BXD strains by
several independent labs and data is publicly available in
GeneNetwork (www.genenetwork.org), a public repository of
genetic and phenotypic data as well as a resource for multivariate
genetic analysis of complex traits in genetic reference populations
[22,23,24,25].
In the present study we systematically defined genetic variation
in basal levels of the neurosteroid DOC and dexamethasone-
induced DOC responses across the BXD strains. We further
analyzed genetic correlations between DOC levels and genetic or
phenotypic data previously determined in the BXD panel by
multiple independent laboratories and available in GeneNetwork.
Results
Basal DOC levels in BXD strains
We examined basal DOC levels across the BXD strains,
including their parental strains and the B6D2 F1 hybrid. The data
was obtained from the saline-treated mice. There was significant
genetic variation in basal DOC levels in both cerebral cortex and
plasma, as revealed by comparison of basal DOC levels across all
the strains by one-way ANOVA. Figure 1a shows cerebral cortical
DOC levels across the BXD strains examined (n=42) as well as,
the B6D2 F1 and the parental strains. Values range between 1.4
and 12.2 ng/g resulting in 8.7-fold genetic variation
[F(43,246)=4.33, p,0.0001] of this trait. Heritability (h
2) for this
trait was estimated to be approximately 0.37 using a conservative
measure (the intraclass correlation, see http://www.genenetwork.
org/glossary.html#H) or ,0.68 using the Hegmann and
Possidente’s method [26]. Basal plasma DOC levels across the
BXD strains examined (n=47), the B6D2 F1 hybrid and the
parental strains range between 2.8 and 12.1 ng/ml, resulting in a
4.3-fold genetic variation [F(48,282)=3.69, p,0.0001] (Figure 1b).
Heritability (h
2) for this trait was estimated to be ,0.32 using the
intraclass correlation and ,0.65 using the Hegmann and
Possidente’s method. The similar pattern of variation resulted in
a positive correlation between plasma vs. cerebral cortical basal
DOC levels across these strains (Pearson r=0.78, p,0.0001;
Spearman r=0.74, p,0.0001, n=43 strains, including parents
and F1 hybrids; figure 2). This indicates that approximately 60%
of the variance is shared between these traits and that as much as
40% is unique to each tissue source.
Genetic correlations with behavioral phenotypes across
the BXD strains
Variation in basal DOC levels in both plasma and cerebral
cortex was linked to several ethanol and anxiety phenotypes
previously characterized across the BXD strains by other
laboratories whose data are available in GeneNetwork (Figures 3
and 4). Basal DOC levels are positively correlated with increased
ethanol-induced sedation (Pearson’s r=0.63, p=0.008, Spear-
man’s r=0.64, p=0.006, n=16; [27]), ethanol-induced ataxia
(Pearson’s r=0.49, p=0.024, Spearman’s r=0.57, p=0.006,
n=21; [28]), and ethanol-induced corticosterone levels (Pearson’s
r=0.67, p=0.003, Spearman’s r=0.73, p=0.0005, n=17; [29])
(Figure 3).
Correlations between basal plasma DOC levels and anxiety-
associated phenotypes are moderately high (Figure 4). Basal DOC
levels are associated with anxiety-like behaviors, measured
15 minutes after restraint stress in the light/dark box test
(Pearson’s r=20.56, p=0.011, Spearman’s r=20.63, p=0.003,
n=19; Putman & Miles, manuscript submitted, GN ID: 10960),
and in the elevated zero maze (Pearson’s r=20.37, p=0.012,
Spearman’s r=20.34, p=0.022, n=44; Cook et al., unpublished,
GN ID: 12467).
Figure 1. Variation in basal DOC levels across the BXD strains. Mice were injected with saline at 8:00 am and were sacrificed 6 hours later.
Data are expressed as ng/g (cerebral cortex) or ng/ml (plasma) and are means 6 SEM of values from 2–9 mice per strain. The x axis reports the BXD
strain number; C57BL/6J (B6), DBA/2J (D2) and B6D2 F1 hybrid are also indicated. Strains are plotted in order from the lowest to the highest DOC
levels for cerebral cortex (42 BXD strains) or plasma (47 BXD strains), respectively. One-way ANOVA was used to estimate significant genetic variation.
doi:10.1371/journal.pone.0018405.g001
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are reported in Table S1 and Figure S1, respectively. Interestingly,
both cerebral cortical and plasma basal DOC levels were correlated
with adrenal weight (GN ID: 11299) [30], which is important
because adrenals are the major source of DOC production. Basal
DOC levels are also correlated with behavioral measures of
morphine and cocaine sensitivity, seizures susceptibility, pain
sensitivity, sweet/bitter taste responses, number of tyrosine
hydroxylase neurons, D1 dopamine receptor receptors (DRD1) in
several brain regions, dopamine transporter SLC6A3 density in
prefrontal cortex, and the number of 5-bromo-29-deoxyuridine
(BrdU)-labeled cells, a measure of adult neurogenesis.
Mapping the QTLs for DOC
Variation in basal cerebral cortical DOC levels across the BXD
strains was mapped using genetic and bioinformatics tools in
GeneNetwork. A significant quantitative trait locus (QTL) was
detected on chromosome 4 with a peak at 60 Mb (support interval
,46–63 Mb), a likelihood ratio statistic (LRS) of 29 and a high B
allele (Figure 5a). Suggestive loci mapped on chromosomes 3 (B
allele high), 13 (D allele high), 15 (B allele high), 17 (D allele high)
and 18 (D allele high). Basal DOC levels in cerebral cortex and in
plasma have substantial shared correlation, but the overlap of
QTLs was modest. Corresponding mapping for basal plasma
DOC levels revealed a significant QTL on chromosome 14
between 93 and 100 Mb, (LRS of 19 and a high B allele) and three
suggestive QTLs on chromosomes 4 (B allele high), 10 (D allele
high), and 17 (D allele high) (Figure 5b). One of these suggestive
loci, that on chromosome 4, precisely overlapped the significant
locus for basal cortical DOC levels. The suggestive loci on
chromosome 17 for both DOC phenotypes have the same location
near the major histocompatibility complex, the same effect size
(,1 ng/g per allele), and the same polarity (high D alleles).
We used extensive available information regarding sequence
variants between the B6 and D2 progenitor strains and gene
expression data across the BXD panel to identify potential candidate
genes for the two significant QTLs on chromosomes 4 and 14. The
chromosome 4 interval contained ,108 genes (GeneNetwork
Interval Analyst, UCSC mm9 database) of which, 16 contained
SNPs that distinguish between B and D haplotypes and that are
predicted to produce non-conservative amino acid changes (http://
genenetwork.org/webqtl/main.py?FormID=snpBrowser) (Table
S2). Analysis of these variants using PolyPhen highlighted eight
SNPs in six genes (Nipsnap3b, Zfp462, D730040F13Rik, Zkscan16,
Susd1 and Slc46a2) that are likely to be deleterious (Table S2).
Additionally, analysis of BXD expression data from whole brain,
prefrontal cortex, and liver identified significant cis-acting expression
QTLs (cis-eQTLs) in 11 genes within the chromosome 4 support
interval (Table S3). The chromosome 14 QTL contained only 26
genes of which 5 had B vs. D non-conservative SNPs in coding
regions (Table S4), only 1 SNP (on the Tdrd3 gene) predicted to be
deleterious by PolyPhen and 8 genes had strong cis-eQTLs in whole
brain, prefrontal cortex or liver expression datasets (Table S5). Of
these potential gene candidates, tudor domain containing 3 (Tdrd3)a t
88.9 Mbonchromosome14hadacis-eQTLacrossmultipledatasets
and showed a very strong correlation (Pearson r=20.79 in
prefrontal cortex dataset) with plasma DOC levels across BXD
strains (Figure S2).
None of the correlated behavioral phenotypes for ethanol or
anxiety (Figures 3 and 4) showed a suggestive or significant QTL
within the support intervals of the basal plasma or cerebral cortical
DOC QTLs. However, pain sensitivity (Table S1) has a significant
QTL on chromosome 4, similar to cerebral cortical DOC levels.
Suggestive QTLs on the chromosome 4 support interval for basal
cerebral cortical DOC levels are found for the kidney morphology
Figure 2. Correlation between cerebral cortical vs. plasma
basal DOC levels across the BXD strains. DOC levels are expressed
in ng/g (cerebral cortex) or ng/ml (plasma). Gray squares represent BXD
strains, black squares are C57BL/6J (B6) and DBA/2J (D2) strains and
dark gray square is the B6D2 F1 hybrid. Pearson r=0.78, p,0.0001;
Spearman r=0.74, p,0.0001; n=43.
doi:10.1371/journal.pone.0018405.g002
Figure 3. Genetic correlations between basal cerebral cortical or plasma DOC levels and behavioral phenotypes for ethanol
sensitivity previously characterized in the BXD strains. Behavioral data for ethanol sensitivity has been collected by multiple independent labs
and has been obtained from GeneNetwork (www.genenetwork.org). A) Pearson’s r=0.63, p=0.008, Spearman’s r=0.64, p=0.006, n=16; Rodriguez
et al., 1994, GN ID 10586. B) Pearson’s r=0.49, p=0.024, Spearman’s r=0.57, p=0.006, n=21; Kirstein et al., 2002, GN ID 10350. C) Pearson’s r=0.67,
p=0.003, Spearman’s r=0.73, p=0.0005, n=17; Roberts et al., 1995, GN ID 10573.
doi:10.1371/journal.pone.0018405.g003
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section in males, GN ID: 11020, Star et al., unpublished; Pearson
r=0.54, p=0.007, n=23) and for the photoreceptor density trait
(GN ID: 10891, Guo et al., unpublished: Pearson r=20.49,
p=0.003, n=33, Table S1). No other traits were found to map in
the support interval of the chromosome 14 QTL, associated with
basal plasma DOC levels.
Identification of genetic networks correlated with DOC
levels
In light of the fact that DOC is known to regulate genes via
nuclear receptors [31], we subsequently identified genes showing
whole brain expression that correlated (Pearson’s r) with basal
cortical DOC levels across BXD strains, using existing microarray
data within GeneNetwork (Table S6). A total of 458 genes showed
significant expression correlations (p,0.001) with cortical DOC
levels. Figure 6 shows the top two scoring gene networks obtained
by Ingenuity Pathway analysis of this DOC-correlated gene set.
Although varying cellular and biological functions were represent-
ed by genes in these genetic networks, the presence of multiple
genes functioning in inflammation (Fig. 6A), vesicle trafficking
(Fig. 6A) and nuclear receptor signaling (Fig. 6A and 6B) was
particularly significant. We further determined if any of the 458
genes correlating with basal cerebral cortical DOC levels (Figure 6)
are contained within the QTL for cerebral cortical DOC or show
trans-linkage to cerebral cortical DOC levels. The only gene
correlated with brain DOC levels and with trans-eQTL to the
support interval of the chromosome 4 QTL is Kiaa0368,
proteasome-associated protein ECM29 homolog (Pearson
r=0.76, p,0.001).
Dexamethasone suppression of DOC in BXD strains
Figure 7a shows the dexamethasone-induced changes in
cerebral cortical DOC levels. Data is expressed as % change vs.
the respective saline-treated strains. We observed a 4.4-fold
variation in dexamethasone-induced changes in cerebral cortical
DOC levels (range 222.6% to 299.1%); however, the majority of
the strains showed a very strong suppression in DOC levels (270
to 290%). Figure 7b shows the dexamethasone-induced changes
in plasma DOC levels across the BXD strains. The pattern is very
similar to cerebral cortex; we observed a 4.1-fold variation from
221.4% to 288.7%, with the majority of the strains showing
greater than 70% suppression. In fact, there was a positive
correlation between percent dexamethasone-induced changes in
plasma vs. cerebral cortical DOC levels, across the strains so far
examined (Pearson’s r=0.77, p,0.0001; Spearman’s r=0.65,
p,0.0001, n=45, data not shown). The interval mapping analysis
identified a suggestive QTL on chromosome 2 for the dexameth-
asone-induced changes in plasma DOC levels (Figure 8b).
Variations in the dexamethasone-induced changes (%) in
cerebral cortical and plasma DOC levels were also correlated
with several phenotypes for ethanol sensitivity and anxiety,
previously characterized in the BXD strains. Table S7 summarizes
some of these significant correlations. Dexamethasone suppression
of DOC levels was positively correlated with ethanol-induced
ataxia, ethanol-induced hypothermia, ethanol-induced locomotor
activity, and ethanol-induced anxiolysis. Dexamethasone suppres-
sion of DOC was inversely correlated with anxiety in some tests
(light-dark box), but not others (elevated zero maze, locomotion in
the center of open field arena). Furthermore, dexamethasone
suppression of DOC was inversely correlated with volume and
weight of several brain regions, as well as with neurogenesis in the
rostral migratory stream.
We specifically searched for correlations between basal DOC
levels or dexamethasone-induced changes in DOC levels and
ethanol consumption, preference, ethanol-induced place prefer-
ence or ethanol consumption following schedule-induced polydip-
sia. None of these correlations were found to be significant.
Discussion
This study identifies the genetic regulation of basal and
dexamethasone-induced levels of the neurosteroid DOC and links
the genetic variation of this steroid with behavioral phenotypes
and gene expression profiles previously determined across the
BXD strains by multiple independent labs. In addition, we present
evidence for a highly significant correlation between brain DOC
Figure 4. Genetic correlations between basal plasma DOC levels and phenotypes for anxiety-like behavior previously characterized
in the BXD strains. Data for anxiety-like behavior has been collected by two independent labs and has been obtained from GeneNetwork (www.
genenetwork.org). A) Pearson’s r=20.56, p=0.011, Spearman’s r=20.63, p=0.003, n=19; Putman & Miles, manuscript submitted, GN ID 10960. B)
Pearson’s r=20.37, p=0.012, Spearman’s r=20.34, p=0.022, n=44; Cook et al., unpublished, GN ID 12467.
doi:10.1371/journal.pone.0018405.g004
Genetic Analysis of Deoxycorticosterone Levels
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18405and regulation of brain gene networks related to neuronal and
nuclear receptor function.
To the best of our knowledge this is the first study to examine
the genetic basis of variation in neurosteroid levels. Variation in
basal levels of DOC resulted in heritability values of ,0.37 and
,0.32 even though basal levels did not significantly differ
between the parental strains. Although the within-strain sample
size is small for some of the strains (values range between 2 and
9), the total number of strains examined is greater than 40, thus
allowing us enough power for QTL detection using recombinant
inbred strains [32]. QTLs for basal DOC levels were identified
in both cerebral cortex and plasma. The QTL for basal cerebral
cortical DOC levels is located on chromosome 4 within a wide
region comprised between 46 and 63 megabases. In contrast, the
QTL for basal plasma DOC levels is located on chromosome 14
between 93 and 100 megabases; however, a suggestive QTL for
basal plasma DOC levels was also identified on chromosome 4.
It is perhaps somewhat surprising that there are no shared
significant QTLs between plasma and cortical basal DOC levels,
given the strong correlation (r=0.78) between the two
phenotypes. However, it is likely that the non-shared variance
(,40%) between the two traits is largely genetic and driving the
two different QTLs. On the other hand, the involvement of
different chromosomes, associated with basal DOC levels
measured in the brain vs. the periphery, may reflect differential
gene regulation of basal DOC biosynthesis in the cerebral cortex
vs. adrenal. Indeed, adrenal glands are the major source of DOC
production in the circulation. In agreement, a strong linkage
between basal DOC levels and adrenal weight was observed for
both cerebral cortex and plasma. Although these QTLs need to
be confirmed and mapped at higher resolution by future studies,
some of the candidate genes described in this analysis may
provide novel information regarding the regulation of circulating
DOC levels.
Figure 5. Genome-wide interval mapping plot for basal cerebral cortical and plasma DOC levels across the BXD strains and their
parental strains. Mice were injected with saline at 8:00 am and were sacrificed 6 hours later. A) Likelihood ratio statistic (LRS) scores for basal
cerebral cortical DOC levels across the entire genome show a significant QTL on chromosome 4 (purple arrow) and suggestive QTLs on chromosomes
3, 13, 15, 17 and 18 (red arrows). B) LRS scores for basal plasma DOC levels across the entire genome show a significant QTL on chromosome 14
(purple arrow) and suggestive QTLs on chromosomes 4, 10 and 17 (red arrows). The y axis and the thick blue lines provide the LRS of the association
between the trait and the genotypes of markers. The two horizontal lines are the suggestive (gray) and significance (red) thresholds computed using
1000 permutations. A positive additive coefficient (green line) indicates that D alleles increase trait values. A negative additive coefficient (red line)
indicates that B alleles increase trait values.
doi:10.1371/journal.pone.0018405.g005
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regulatory molecules by actions on nuclear receptors [31,33]. In
light of this we hypothesized that cortical DOC could be altering
brain gene expression. We thus examined the correlation between
cerebral cortical DOC levels and whole brain gene expression
profiles across the BXD strains. Whole brain expression data was
used as an exploratory screen since the possible regions of DOC
action on brain gene expression are unclear. The networks
portrayed in Figure 6 are suggestive of direct DOC effects on gene
expression and support previous evidence from the literature for a
role of neurosteroids in inflammation, synaptic transmission and
neurotransmitter release [34,35,36,37,38]. Future studies will be
required to validate the role of neurosteroids in regulation of these
genetic networks.
Variation in basal levels of DOC was linked to several
behavioral phenotypes previously determined in the BXD strains
Figure 6. Genetic network analysis of brain gene expression correlating with basal cerebral cortical DOC levels across BXD strains.
Genetic correlations (Pearson’s r) between whole brain gene expression and basal cerebral cortical DOC levels were generated within GeneNetwork
(www.genenetwork.org). A total of 458 genes (496 probesets) had r values of p,0.001 (Table S6). Gene networks were generated from this DOC gene
set by Ingenuity Pathway Analysis. The top two scoring networks are portrayed. All colored gene symbols were contained within the DOC-correlated
gene set with either positive (red) or negative (green) expression correlations with DOC across 20 BXD lines. Arrows indicate representative genes
functioning in nuclear receptor action (black), inflammation (red), or vesicular trafficking and synaptic transmission (blue).
doi:10.1371/journal.pone.0018405.g006
Figure 7. Variation in dexamethasone suppression of DOC levels across the BXD strains. Mice were injected with dexamethasone
(0.075 mg/kg, sc) or saline at 8:00 am and were sacrificed 6 hours later. Data are expressed as % change of the average for dexamethasone-treated
mice vs. the average for the respective saline-treated mice (n=2–9/group/strain). The x axis reports the BXD strain number; C57BL/6J (B6), DBA/2J
(D2) and B6D2 F1 hybrid are also indicated. Strains are plotted in order from the lowest to the highest suppression of DOC levels for cerebral cortex
(42 BXD strains) or plasma (47 BXD strains), respectively.
doi:10.1371/journal.pone.0018405.g007
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between basal DOC levels and traits for ethanol sensitivity is of
particular importance. Studies in rodents and humans have
suggested that GABAergic neuroactive steroids may play a role in
ethanol sensitivity. Systemic administration of ethanol increases
brain and serum levels of DOC and the GABAergic neuroactive
steroids in rodents [2,3,39,40,41]. The ethanol-induced elevations
of GABAergic neuroactive steroids contribute to several behav-
ioral effects of ethanol in rodents, such as anticonvulsant effects
[40], sedation [5], impairment of spatial memory [42,43],
anxiolytic-like [44] and antidepressant-like [45] actions. Each of
these behavioral responses is prevented by pretreatment with the
neurosteroid biosynthesis inhibitor finasteride and/or by prior
adrenalectomy. Furthermore, administration of finasteride atten-
uates the subjective effects of ethanol in individuals homozygous
for the A allele at the GABAA receptor a2 subunit (GABRA2) gene
polymorphism but not in individuals with the G allele (associated
with alcohol dependence), suggesting a role for neuroactive
steroids in mediating ethanol sensitivity in humans [46]. It has
been hypothesized that GABAergic neuroactive steroids may
protect against the risk for ethanol dependence [47,48]. Dimin-
ished elevations of neuroactive steroids following ethanol exposure
would result in reduced sensitivity to the anxiolytic, sedative,
anticonvulsant, cognitive-impairing, and discriminative stimulus
properties of ethanol [47]. Reduced sensitivity to ethanol is
associated with greater risk for the development of alcoholism in
individuals with genetic vulnerability to alcoholism [49,50,51,
52,53]. The finding that those mouse strains with higher basal
DOC levels also show greater ethanol sensitivity is consistent with
this hypothesis. Higher basal DOC levels may reflect greater
steroidogenesis in general or may result in higher production of its
neuroactive metabolite THDOC. Studies are under way to
examine this hypothesis.
Genetic linkage with behavioral phenotypes of ethanol sensitiv-
ity suggests overlap in the genes that control ethanol-induced
sedation, ataxia, seizure susceptibility, locomotion, corticosterone
Figure 8. Genome-wide interval mapping for the dexamethasone-induced changes in (A) cerebral cortical and (B) plasma DOC
levels across the BXD strains and their parental strains. Mice were injected with dexamethasone (0.075 mg/kg, sc) or saline at 8:00 am and
were sacrificed 6 hours later. The % change of the average for dexamethasone-treated mice vs. the average for the respective saline-treated mice has
been used for analysis. Panels show likelihood ratio statistic (LRS) scores across the entire genome. The y axis and the thick blue lines provide the LRS
of the association between the trait and the genotypes of markers. The two horizontal lines are the suggestive (gray) and significance (red) thresholds
computed using 1000 permutations. A suggestive QTL on chromosome 2 (red arrow) was identified. A positive additive coefficient (green line)
indicates that D2 alleles increase trait values. A negative additive coefficient (red line) indicates that B6 alleles increase trait values.
doi:10.1371/journal.pone.0018405.g008
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note that variation in basal DOC levels was also linked to some
anxiety phenotypes and seizure susceptibility. This is not
surprising, given that systemic administration of neuroactive
steroids induces anxiolytic and anticonvulsant properties
[54,55,56] and neuroactive steroid levels are altered in several
psychiatric disorders involving stress and anxiety [1,57,58].
Higher basal DOC levels were also linked to greater anxiety
after restraint stress. Acute stress (like acute ethanol) activates the
HPA axis and increases brain and circulating levels of GABAergic
neuroactive steroids [1] as well as corticosterone, the major
corticosteroid synthesized in rodents from DOC. GABAergic
neuroactive steroids have anxiolytic properties when administered
systemically [54,55]. Thus, we might have predicted that those
strains with higher basal DOC levels would have been less
susceptible to anxiety, because of the protective role exerted by its
neuroactive metabolite, THDOC. However, the heightened
anxiety after restraint stress suggests that DOC is primarily
metabolized to corticosterone. It should be noted that we found no
correlation between basal DOC levels in our study and basal
corticosterone levels measured 1 or 6 hours following saline
injection [29]. This data is limited to the original panel of the BXD
strains; thus, to better understand this relationship, studies of
corticosterone levels in all the strains available, including the
advanced panel, are warranted. Furthermore, the ratio of
corticosterone to GABAergic metabolites after stress may provide
more insight into the relationship between DOC levels and
anxiety-like behavior.
Previous studies had suggested that dexamethasone suppression
of DOC levels might correlate with ethanol consumption or
preference, based on higher voluntary ethanol consumption in
cynomolgus monkeys that exhibited weak suppression of DOC in
response to dexamethasone [9]. In the monkey studies, ethanol
consumption was measured across twelve months of voluntary
consumption preceded by three months of scheduled induction of
alcohol drinking, while drinking studies in the mice were measured
across two to fifteen days with no induction procedure [27,59,60]
(see also Matthews et al., 2009, GN ID 11297; Lopez et al., 2010,
GN IDs: 12574–12580; Cook et al., 2010, GN IDs 12565 and
12586, all unpublished on GeneNetwork). The fact that
dexamethasone suppression of DOC levels was not predictive of
ethanol consumption or preference across BXD strains is likely
related to differences in the drinking paradigms. Alternatively,
species differences may account for this discrepancy. Finally, it is
likely that multiple genes located on different chromosomes may
influence ethanol consumption and this may contribute to
differential correlations between this trait and DOC suppression
by dexamethasone.
This study focused on male mice only. Neurosteroid basal levels
in female mice vary in relation to the estrus cycle phase [61].
Therefore, sex differences in basal DOC levels are likely to occur.
Furthermore, sex differences and sex by strain interactions are not
uncommon across studies of the BXD strains [62,63,64]. Future
studies are needed to examine any potential sex differences in the
genetic regulation of neurosteroid levels.
In conclusion, we have identified QTLs for basal levels of the
neurosteroid DOC. Both basal DOC levels and dexamethasone
suppression of DOC are positively correlated with ethanol
sensitivity suggesting that the neurosteroid DOC could serve as
a useful biomarker of alcohol phenotypes. Furthermore, DOC
levels appear to be responsible for the regulation of networks of
genes involved in the neuronal processes that underlie many
aspects of brain function and likely the correlated ethanol
phenotypes.
Materials and Methods
Animals
Male B6, D2 and B6D2 F1 hybrid mice (8 weeks old) were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA).
BXD strains were either purchased from The Jackson Laboratory,
or were acquired from the vivarium at the University of Tennessee
Health Science Center (Memphis, TN, USA). After arrival at the
animal facility, mice were allowed to acclimate for at least one
week. They were housed four to six per cage under 12 h light,
12 h dark cycle (lights on from 0700 to 1900 h) and at a constant
temperature of 2262uC and relative humidity of 65%. They had
free access to water and standard laboratory food at all times.
The BXD recombinant inbred strains have proved to be an
extremely valuable reference population to study networks of
phenotypes and their modulation by gene variants [18,19,20,21].
The parental strains, B6 and D2, have been sequenced, and
approximately two million SNPs between them have been
identified. Most studies of BXD strains since 2001 have exploited
,3,800 informative markers (mainly SNPs and microsatellites)
selected from a set of ,15,000 markers (see details in [20] and
[65]). The full marker set can be downloaded as a text file at
http://www.genenetwork.org/dbdoc/BXDGeno.html. The mean
interval between informative markers is ,0.7 Mb.
Dexamethasone Administration
Mice were injected subcutaneously (sc) with dexamethasone
(0.075 mg/kg) or saline at 8:00 am (lights on from 0700 to 1900 h)
and were returned to their home-cage until sacrifice by
decapitation 6 hours later. This protocol was adapted from
previous work showing that administration of dexamethasone
0.1 mg/kg, sc, suppressed plasma corticosterone levels in B6 mice
6 hours after its administration [66]. The dose of dexamethasone
was chosen because it induced a differential response in the
parental strains [67]. To control for circadian fluctuations in DOC
levels, the experiments were all performed at the same time of the
day, as stated above. Furthermore, care was taken to minimize
stress which would affect DOC levels. Following injections, all
mice were left undisturbed in their home cage for 6 hours until
sacrifice. Blood was collected from the trunk immediately after
decapitation into lithium-heparin microtainer tubes (Becton
Dickinson, Franklin Lakes, NJ, USA). It was centrifuged (1750 g
for 15 min at 4uC) and serum samples were stored in plastic
minivials at 280uC until use. The brain was rapidly extracted
from the skull, dissected on ice, frozen on dry ice and stored at
280uC until DOC extraction and analysis. Animal care and
handling throughout the experimental procedures followed
National Institutes of Health Guidelines under University of
North Carolina School of Medicine Institutional Animal Care and
Use Committee approved protocols (Protocol 07-131). Adequate
measures were taken to minimize pain or discomfort of the
animals.
DOC Radioimmunoassay
DOC was measured in mouse cerebral cortex and plasma by
radioimmunoassay (RIA) as previously described [2,9], with minor
modifications. Individual cerebral cortexes were weighed, sus-
pended in 3 ml of phosphate buffer and homogenized on ice with
a sonic dismembrator. Homogenates were spiked with 1000 cpm
of [
3H]DOC (Specific activity=50 Ci/mmol; American Radiola-
beled Chemicals, Inc. Saint Louis, MO, USA) for recovery
estimation. Samples were extracted three times in 4 ml aliquots of
ethyl acetate. Plasma samples (100 ml) were extracted twice with
2 ml ethyl acetate/hexane (3:2); 1000 cpm of [
3H]DOC were
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from cerebral cortex are resuspended in 2 ml RIA buffer, of which
0.5 ml is used for the assay (run in duplicate) and 0.5 ml is used for
recovery determination. The dried extracts from plasma are
resuspended in 1.5 ml RIA buffer, of which 0.5 ml is used for the
assay (run in duplicate) and 0.3 ml is used for recovery
determination. The DOC antiserum (MP Biomedicals, Solon,
OH, USA) was diluted according to manufacturer’s instructions.
This antiserum is highly specific for DOC as shown by the
following cross-reactivity tests: DOC 100%, 3a,5a-THDOC
4.7%, progesterone 2.5%, corticosterone 1.7%. Less than 1%
cross-reactivity was observed for 3a,5a-THP, 3a-hydroxy-pregn-
4-en-20-one, pregnenolone, 20-hydroxy-pregnen-4,3-one, testos-
terone, androstenedione, 17a-hydroxyprogesterone, 11-deoxycor-
tisol, 5a-dihydrotestosterone, cortisol, cholesterol, 17b-estradiol,
estrone, and estriol. Unknown samples were compared to
concurrently run standards using a one-site competition model
and adjusted for extraction efficiency. DOC values are expressed
as ng/g of cerebral cortex or ng/ml of plasma. Intra-assay and
inter-assay coefficients of variation were 5.6% and 13.5%,
respectively for plasma and 6.9% and 12.2% for cerebral cortex.
Statistical and bioinformatic analysis
ANOVAs were performed using a commercially available
statistical program (GraphPad Prism 4.0, GraphPad Software,
San Diego, CA, USA). Genetic data was analyzed using the
statistical software available in GeneNetwork (www.genenetwork.
org) and the R/QTL program within the R statistical framework.
GeneNetwork allows for the analysis of networks of genes,
transcripts and classic phenotype data sets [25]. Datasets for basal
and dexamethasone-induced DOC levels were subjected to simple
interval mapping analysis using Haley–Knott regression equations.
Interval mapping was performed using the Haldane function, a
1 cM window, and marker maps for each chromosome that are
very dense relative to recombination frequency in this cross. The
thresholds for statistically significant (p value,0.05) and suggestive
(p value,0.63) [68] genome-wide linkage were determined based
on permutation tests [69]. Support intervals were calculated using
R/QTL with a 97% Bayes credible interval [70]. Correlation
analyses were performed using the log-transformed data in order
to correct for non-normal distributions. Pearson’s product moment
and Spearman’s rank correlations were computed using analytical
tools integrated into GeneNetwork and using data sets of
numerous BXD behavioral and physiological phenotypes, as well
as array data of brain gene expression. Candidate genes for QTL
support intervals were identified by mining the SNP database on
GeneNetwork (http://genenetwork.org/webqtl/main.py?FormID=
snpBrowser) for mis/non-sense polymorphisms between B6 and D2
strains within exons of genes within support intervals and by
PolyPhen analysis (http://coot.embl.de/PolyPhen/). Additionally,
BXD expression data from whole brain (UCHSC BXD Whole Brain
M430 2.0 Nov06 RMA dataset), prefrontal cortex (VCU BXD PFC
Sal M430 2.0 Dec06 RMA dataset), and liver (UNC Agilent G4121A
Liver Males Only LOWESS Stanford Jan06 Dataset) were used
to identify cis-acting expression QTL (cis-eQTL) within QTL
support intervals using GeneNetwork. These cis-eQTLs show
genetic linkage of their mRNA expression at a chromosomal site
overlapping the gene location itself. In this case, it is genetically
driven differences in expression of the candidate gene, rather
than a genetic alteration in gene function per se, that is predicted
to influence the quantitative trait (cerebral cortical DOC levels).
We chose these datasets for mRNA expression correlation due to
known effects of prefrontal cortex on HPA axis activity and drug
addiction [71,72,73] and the role of the liver in steroid
metabolism [74]. An adrenal BXD dataset was not currently
available.
Molecular and genetic networks potentially regulated by
cerebral cortex DOC were identified by correlating DOC levels
with BXD expression data in GeneNetwork from whole brain
(UCHSC BXD Whole Brain M430 2.0 Nov06 RMA dataset)
using Pearson’s product moment with a somewhat relaxed
statistical filter (p,0.001) to enable network analysis. Pearson
correlations were further analyzed for potential gene-gene network
interactions using the Ingenuity Pathway Analysis bioinformatics
platform. This platform superimposes gene set information on
gene networks constructed from prior information from the
biomedical literature, protein-protein interaction databases,
known biochemical pathways and miRNA or transcription factor
regulatory interactions.
Supporting Information
Figure S1 Cluster maps to detect linkages for basal DOC levels
in the cerebral cortex (A) and plasma (B). The demarcation along
the long axis represents chromosomes 1 to X; red-yellow and blue-
green color gradations code for intensity of linkage with higher
trait values for D2 allele and B6 allele, respectively.
(TIFF)
Figure S2 The upper panel shows the interval map for Tdrd3 in
the prefrontal cortex (PFC) BXD saline dataset from GeneNet-
work. This confirms a cis-eQTL at the position of the Tdrd3 gene
and the chromosome 14 QTL for basal plasma DOC. The lower
panel shows correlation (Pearson’s) of Tdrd3 expression in PFC
with plasma DOC levels.
(TIFF)
Table S1 Pearson’s correlations of the log-transformed basal
DOC data are reported. LORR: loss of righting reflex; HIC:
handling-induced convulsions; VTA: ventral tegmental area; SN:
substantia nigra.
(DOC)
Table S2 Genes containing nonsynonymous mutations between
C57BL/6J (B6) and DBA/2J (D2) within the QTL support
interval on chromosome 4.
(DOC)
Table S3 Cis-eQtTLs in the chromosome 4 support interval
were identified using the GeneNetwork resources. The tissue for
each database is indicated in bold. PFC: prefrontal cortex.
(DOC)
Table S4 Genes containing nonsynonymous mutations between
C57BL/6J (B6) and DBA/2J (D2) within the QTL support
interval on chromosome 14.
(DOC)
Table S5 Cis-eQtTLs in the chromosome 14 support interval
were identified using the GeneNetwork resources. The tissue for
each database is indicated in bold. PFC: prefrontal cortex.
(DOC)
Table S6 Gene expression correlations between basal cortical
DOC and whole brain mRNA expression were done in GeneNet-
work using the following parameters: Trait : BXDPublish : 12568,
Database : UCHSC BXD Whole Brain M430 2.0 (Nov06) RMA,
Citations: Please see http://132.192.47.32/reference.html.
(DOC)
Table S7 Pearson’s correlations of the log-transformed DOC
data are reported. HIC: handling-induced convulsions.
(DOC)
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